Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its target price hoisted by equities researchers at Leerink Partners ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common ...

Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial ...

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Analysts at Leerink Partnrs cut their Q4 2025 earnings per share (EPS) estimates for 908 Devices in a note issued to ...

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting as book-running manager for the proposed offering. An automatically ...

The decline in 89bio's stock price reflects investor reaction to the potential dilution of shares due to the proposed offering. When a company issues additional stock, it can lead to a reduction in ...

Goldman Sachs & Co (NYSE:GS). LLC, Leerink Partners, and BofA Securities are leading the offering as book-running managers, with Cantor also serving as a book-running manager. The announcement ...

SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...